| Previous close | 133.45 |
| Open | 133.27 |
| Bid | 132.60 x 100 |
| Ask | 136.33 x 100 |
| Day's range | 132.90 - 134.79 |
| 52-week range | 109.32 - 137.08 |
| Volume | 4,150,284 |
| Avg. volume | 5,532,522 |
| Market cap | 361.53B |
| Beta | 0.64 |
| PE ratio (TTM) | 22.64 |
| EPS (TTM) | 5.95 |
| Earnings date | 17 Oct 2017 |
| Dividend & yield | 3.36 (2.52%) |
| Ex-dividend date | 2017-08-25 |
| 1y target est | 136.89 |
- Associated Press•7 hours ago
AP Top Extended Financial Headlines at 11:19 p.m. EDT
Iran's new telecommunications minister says Twitter is ready to talk about unblocking access to the microblogging site
- Associated Press•7 hours ago
AP Top Extended Financial Headlines at 11:19 p.m. EDT
Iran's new telecommunications minister says Twitter is ready to talk about unblocking access to the microblogging site
Reuters•12 hours agoMassive California verdict expands J&J's talc battlefield
A massive California verdict in a lawsuit alleging Johnson & Johnson's (JNJ.N) talc-based products cause cancer has opened a new front in the litigation, upending the company's hopes that the cases were only gaining traction in Missouri, legal experts said. The $417 million award by California jury to a California resident suggested so-called forum-shopping, in which parties seek to file cases in whichever jurisdictions seem most favorable, may not be the main problem facing J&J as it wrestles with some 4,800 outstanding talc lawsuits. J&J, which denies any link between talc and cancer, said in a statement it would appeal Monday's verdict but declined further comment.
